IL318533A - Nlrp3 inflammasome inhibitors - Google Patents

Nlrp3 inflammasome inhibitors

Info

Publication number
IL318533A
IL318533A IL318533A IL31853325A IL318533A IL 318533 A IL318533 A IL 318533A IL 318533 A IL318533 A IL 318533A IL 31853325 A IL31853325 A IL 31853325A IL 318533 A IL318533 A IL 318533A
Authority
IL
Israel
Prior art keywords
nlrp3 inflammasome
inflammasome inhibitors
inhibitors
nlrp3
inflammasome
Prior art date
Application number
IL318533A
Other languages
Hebrew (he)
Inventor
Xiaobin Ge
Henri Mattes
Zhicong Shi
Mei Xia
Ning Ye
Original Assignee
Novartis Ag
Xiaobin Ge
Henri Mattes
Zhicong Shi
Mei Xia
Ning Ye
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag, Xiaobin Ge, Henri Mattes, Zhicong Shi, Mei Xia, Ning Ye filed Critical Novartis Ag
Publication of IL318533A publication Critical patent/IL318533A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
IL318533A 2022-08-03 2023-08-02 Nlrp3 inflammasome inhibitors IL318533A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263370300P 2022-08-03 2022-08-03
CN2023097282 2023-05-30
PCT/IB2023/057819 WO2024028782A1 (en) 2022-08-03 2023-08-02 Nlrp3 inflammasome inhibitors

Publications (1)

Publication Number Publication Date
IL318533A true IL318533A (en) 2025-03-01

Family

ID=87580191

Family Applications (1)

Application Number Title Priority Date Filing Date
IL318533A IL318533A (en) 2022-08-03 2023-08-02 Nlrp3 inflammasome inhibitors

Country Status (20)

Country Link
US (2) US20240067627A1 (en)
EP (1) EP4565326A1 (en)
JP (1) JP7881051B2 (en)
KR (1) KR20250043519A (en)
CN (2) CN119677725A (en)
AR (1) AR130094A1 (en)
AU (2) AU2023318764B2 (en)
CA (1) CA3262660A1 (en)
CL (1) CL2025000285A1 (en)
CO (1) CO2025002057A2 (en)
CR (1) CR20250063A (en)
DO (1) DOP2025000013A (en)
IL (1) IL318533A (en)
JO (1) JOP20250023A1 (en)
MA (1) MA71689A (en)
MX (1) MX2025001273A (en)
PE (1) PE20251255A1 (en)
TW (1) TW202406550A (en)
UY (1) UY40374A (en)
WO (1) WO2024028782A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11618751B1 (en) 2022-03-25 2023-04-04 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives
US11319319B1 (en) 2021-04-07 2022-05-03 Ventus Therapeutics U.S., Inc. Compounds for inhibiting NLRP3 and uses thereof
US12331048B2 (en) 2022-10-31 2025-06-17 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors
TW202545527A (en) 2024-01-16 2025-12-01 英商諾得瑟拉公司 Nlrp3 and glp-1a combination therapies
WO2026057634A1 (en) * 2024-09-11 2026-03-19 Sanofi Crystalline form of a pyridazine nlrp3 inhibitor

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2510997A1 (en) 1981-08-10 1983-02-11 Sanofi Sa NOVEL DERIVATIVES OF METHYL-4-PHENYL-6-PYRIDAZINE, PROCESS FOR THEIR PREPARATION AND ACTIVE MEDICINES ON CENTRAL NERVOUS SYSTEM CONTAINING THE SAME
PT93060B (en) 1989-02-07 1995-12-29 Sanofi Sa METHOD FOR OBTAINING PYRIDAZINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
FR2663326B2 (en) 1989-11-17 1992-10-16 Sanofi Sa PYRIDAZINE DERIVATIVES, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME.
FR2676444B1 (en) 1991-05-16 1995-03-10 Sanofi Elf NOVEL AMINO-3 PYRIDAZINE DERIVATIVES ACTIVE IN THE CENTRAL NERVOUS SYSTEM, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME.
US6602872B1 (en) 1999-12-13 2003-08-05 Merck & Co., Inc. Substituted pyridazines having cytokine inhibitory activity
WO2004078163A2 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
GB0220581D0 (en) 2002-09-04 2002-10-09 Novartis Ag Organic Compound
EP1745039A4 (en) 2004-05-08 2009-07-22 Neurogen Corp 3-aryl-5,6-disubstituted pyridazines
GB0415746D0 (en) 2004-07-14 2004-08-18 Novartis Ag Organic compounds
GB0521508D0 (en) 2005-10-21 2005-11-30 Novartis Ag Organic compounds
WO2008058064A1 (en) 2006-11-07 2008-05-15 Lexicon Pharmaceuticals, Inc. Amine-linked multicyclic compounds as inhibitors of the proline transporter
GB0720444D0 (en) 2007-10-18 2007-11-28 Glaxo Group Ltd Novel compounds
WO2010048149A2 (en) 2008-10-20 2010-04-29 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
WO2010128152A1 (en) 2009-05-07 2010-11-11 Novartis Ag Fused heterocyclic c-glycosides for the treatment of diabetes
US8163704B2 (en) 2009-10-20 2012-04-24 Novartis Ag Glycoside derivatives and uses thereof
KR20120087950A (en) 2009-10-20 2012-08-07 노파르티스 아게 Glycoside derivative and uses thereof
ES2622138T3 (en) 2010-06-23 2017-07-05 Hanmi Science Co., Ltd. New condensed pyrimidine derivatives for the inhibition of tyrosine kinase activity
WO2012016133A2 (en) 2010-07-29 2012-02-02 President And Fellows Of Harvard College Ros1 kinase inhibitors for the treatment of glioblastoma and other p53-deficient cancers
PH12013500246A1 (en) 2010-08-10 2019-10-11 Celgene Avilomics Res Inc Besylate salt of a btk inhibitor
US8835472B2 (en) 2010-09-02 2014-09-16 Boehringer Ingelheim International Gmbh Compounds, pharmaceutical compositions and uses thereof
EP2651405A2 (en) 2010-12-14 2013-10-23 Electrophoretics Limited Casein kinase 1 (ck1 ) inhibitors
CU24152B1 (en) 2010-12-20 2016-02-29 Irm Llc 1,2 OXAZOL-8-AZABICICLO [3,2,1] OCTANO 8 IL AS FXR MODULATORS
US9073947B2 (en) 2011-06-10 2015-07-07 Merck Patent Gmbh Compositions and methods for the production of pyrimidine and pyridine compounds with BTK inhibitory activity
UA111756C2 (en) 2011-11-03 2016-06-10 Ф. Хоффманн-Ля Рош Аг HETEROARYLPYRIDONE AND AZAPIRIDONE COMPOUNDS AS BRUTON TYROSINKINASE INHIBITORS
BR112014012727B1 (en) 2011-11-29 2022-10-25 Ono Pharmaceutical Co., Ltd 6-AMINO-9-[(3R)-1-(2-BUTINOYL)-3-PYRROLIDINYL]-7-(4-PHENOXYPHENYL)-7,9-DIHYDRO-8H-PURI-8-ONE E PHARMACEUTICAL COMPOSITION
EP2858500A4 (en) 2012-06-08 2016-04-06 Biogen Ma Inc INHIBITORS OF BRUTON TYROSINE KINASE
US8729263B2 (en) 2012-08-13 2014-05-20 Novartis Ag 1,4-disubstituted pyridazine analogs there of and methods for treating SMN-deficiency-related conditions
SMT201900344T1 (en) 2012-09-10 2019-07-11 Principia Biopharma Inc Pyrazolopyrimidine compounds as kinase inhibitors
WO2014085474A1 (en) 2012-11-28 2014-06-05 Intercept Pharmaceuticals, Inc. Treatment of pulmonary disease
UY35368A (en) 2013-03-08 2014-10-31 Irm Llc PEPTIDES AND COMPOSITIONS FOR THE TREATMENT OF ARTICULAR DAMAGE
JO3377B1 (en) 2013-03-11 2019-03-13 Takeda Pharmaceuticals Co Pyridinyl and fused pyridinyl triazolone derivatives
PL2989106T3 (en) 2013-04-25 2017-08-31 Beigene, Ltd. Fused heterocyclic compounds as protein kinase inhibitors
SG11201603026PA (en) 2013-11-05 2016-05-30 Novartis Ag Compositions and methods for modulating farnesoid x receptors
US9512084B2 (en) 2013-11-29 2016-12-06 Novartis Ag Amino pyrimidine derivatives
EP3076974A1 (en) 2013-12-05 2016-10-12 Acerta Pharma B.V. Therapeutic combination of a pi3k inhibitor and a btk inhibitor
TN2016000127A1 (en) 2013-12-20 2017-10-06 Novartis Ag Heteroaryl butanoic acid derivatives as lta4h inhibitors.
WO2015110923A2 (en) 2014-01-21 2015-07-30 Acerta Pharma B.V. Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia usng a btk inhibitor
UA122479C2 (en) 2014-01-24 2020-11-25 Дана-Фарбер Кенсер Інстітьют, Інк. Isolated ANTIBODY MOLECULE BINDS TO HUMAN PROGRAMMED DEATH-1 (PD-1) PROTEIN
PL3099717T3 (en) 2014-01-31 2019-10-31 Novartis Ag Antibody molecules to tim-3 and uses thereof
EA201691765A1 (en) 2014-03-14 2016-12-30 Новартис Аг ANTIBODY MOLECULES AGAINST LAG-3 AND THEIR APPLICATIONS
HRP20241236T1 (en) 2014-05-13 2024-12-06 Novartis Ag COMPOUNDS AND PREPARATIONS FOR INDUCING CHONDROGENESIS
CN103965169A (en) 2014-05-30 2014-08-06 彭正中 Compound as well as preparation method and application of compound
WO2016022626A1 (en) 2014-08-06 2016-02-11 Merck Sharp & Dohme Corp. Heterocyclic cgrp receptor antagonists
SG11201702401RA (en) 2014-10-14 2017-04-27 Novartis Ag Antibody molecules to pd-l1 and uses thereof
MX393057B (en) 2014-10-24 2025-03-24 Bristol Myers Squibb Co INDOL CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS.
CN107427468B (en) 2014-12-24 2022-02-25 普林斯匹亚生物制药公司 Site-Specific Administration of BTK Inhibitors
ES2907461T3 (en) 2015-01-20 2022-04-25 Boehringer Ingelheim Animal Health Usa Inc Anthelmintic compounds, compositions and methods of use thereof
US20180008629A1 (en) 2015-01-29 2018-01-11 Yale University Compositions and Methods for Treating NLRP3 Inflammasome-Related Diseases and Disorders
EP3256126B1 (en) 2015-02-09 2024-03-27 F. Hoffmann-La Roche AG Compounds for the treatment of cancer
JP6929792B2 (en) 2015-02-16 2021-09-01 ザ ユニバーシティ オブ クィーンズランド Sulfonylureas and related compounds and their use
MA41598A (en) 2015-02-25 2018-01-02 Constellation Pharmaceuticals Inc PYRIDAZINE THERAPEUTIC COMPOUNDS AND THEIR USES
EP3912979B1 (en) 2015-06-03 2026-03-25 Principia Biopharma Inc. Tyrosine kinase inhibitors
MA42510A (en) 2015-06-10 2018-06-06 Biogen Ma Inc FORMS AND COMPOSITIONS OF BIARYL INHIBITORS OF BRUTON TYROSINE KINASE
EP3359159B1 (en) 2015-10-09 2023-06-07 ACEA Therapeutics, Inc. Pharmaceutical compositions of a pyrrolopyrimidine kinase inhibitor, and methods of making same
TW202510883A (en) 2015-11-04 2025-03-16 德商默克專利有限公司 Methods for treating cancer using pyrimidine and pyridine compounds with btk inhibitory activity
CA3119019C (en) 2015-12-10 2024-06-11 Ptc Therapeutics, Inc. Compounds and methods for treating huntington's disease
US9630968B1 (en) 2015-12-23 2017-04-25 Arqule, Inc. Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof
ES2875384T3 (en) 2016-01-05 2021-11-10 Jiangsu Hengrui Medicine Co Crystal form of BTK kinase inhibitor and method of its preparation
CN109071524A (en) 2016-01-15 2018-12-21 布里格姆及妇女医院股份有限公司 Pyridyl derivatives as EAAT2 activator
KR101865120B1 (en) 2016-06-29 2018-06-08 숭실대학교 산학협력단 Wireless positioning method based on test node and apparatus thereof
IL263815B (en) 2016-06-29 2022-07-01 Principia Biopharma Inc Modified release formulations of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile
EP3272739A1 (en) 2016-07-20 2018-01-24 NodThera Limited Sulfonyl urea derivatives and their use in the control of interleukin-1 activity
TWI674261B (en) 2017-02-17 2019-10-11 美商英能腫瘤免疫股份有限公司 Nlrp3 modulators
CN111372611A (en) 2017-06-14 2020-07-03 Ptc医疗公司 Methods for modifying RNA splicing
CN110914256A (en) 2017-07-07 2020-03-24 英夫拉索姆有限公司 Novel sulfonamide carboxamide compounds
ES3002968T3 (en) 2017-07-14 2025-03-10 Innate Tumor Immunity Inc Nlrp3 modulators
MX2020001425A (en) 2017-08-04 2020-08-06 Skyhawk Therapeutics Inc Methods and compositions for modulating splicing.
MX2020001776A (en) 2017-08-15 2020-03-24 Inflazome Ltd SULFONYLUREAS AND SULFONYLTHIOUREAS AS NLRP<sub>3</sub> INHIBITORS.
US20230152257A1 (en) 2017-09-25 2023-05-18 Skyhawk Therapeutics, Inc. Methods and compositions for screening and identification of splicing
BR112020007058A2 (en) 2017-10-12 2020-10-06 Revolution Medicines, Inc. pyridine, pyrazine, and triazine compounds as allosteric shp2 inhibitors
CN111315733A (en) 2017-11-09 2020-06-19 英夫拉索姆有限公司 Novel sulfonamide carboxamide compounds
BR112020019373A2 (en) 2018-03-27 2020-12-29 Ptc Therapeutics, Inc. COMPOUNDS FOR THE TREATMENT OF HUTINGTON'S DISEASE
JP2021521200A (en) 2018-04-10 2021-08-26 スカイホーク・セラピューティクス・インコーポレーテッド Compounds for the treatment of cancer
SG11202104495YA (en) 2018-04-26 2021-05-28 Aurigene Discovery Tech Ltd Pyridazine derivatives as smarca2/4 degraders
AR119731A1 (en) 2019-05-17 2022-01-05 Novartis Ag NLRP3 INFLAMASOME INHIBITORS
CN115279739B (en) * 2020-03-27 2025-07-22 尼科治疗有限公司 Substituted pyridazine compounds
US20230348437A1 (en) * 2020-07-02 2023-11-02 Denali Therapeutics Inc. Compounds, compositions and methods
TW202231281A (en) 2020-12-25 2022-08-16 大陸商上海拓界生物醫藥科技有限公司 A class of pyridazine containing compounds and medicinal uses thereof
EP4289823A4 (en) * 2021-02-08 2025-02-26 Medshine Discovery Inc. SUBSTITUTED PYRIDAZINE PHENOL DERIVATIVES
US11932630B2 (en) 2021-04-16 2024-03-19 Novartis Ag Heteroaryl aminopropanol derivatives

Also Published As

Publication number Publication date
CL2025000285A1 (en) 2025-06-13
UY40374A (en) 2024-02-15
AU2023318764B2 (en) 2026-04-23
TW202406550A (en) 2024-02-16
CA3262660A1 (en) 2024-02-08
KR20250043519A (en) 2025-03-28
WO2024028782A1 (en) 2024-02-08
AU2023318764A1 (en) 2025-01-09
CR20250063A (en) 2025-03-27
AU2026205161A1 (en) 2026-07-16
PE20251255A1 (en) 2025-05-06
DOP2025000013A (en) 2025-02-28
MX2025001273A (en) 2025-03-07
JP2025525866A (en) 2025-08-07
US20250034114A1 (en) 2025-01-30
US12378222B2 (en) 2025-08-05
MA71689A (en) 2025-05-30
CO2025002057A2 (en) 2025-03-06
US20240067627A1 (en) 2024-02-29
CN121873039A (en) 2026-04-17
CN119677725A (en) 2025-03-21
JOP20250023A1 (en) 2025-01-30
EP4565326A1 (en) 2025-06-11
JP7881051B2 (en) 2026-06-26
AR130094A1 (en) 2024-10-30

Similar Documents

Publication Publication Date Title
LT4363406T (en) Nlrp3 inflammasome inhibitors
IL318258A (en) Novel nlrp3 inflammasome inhibitors
IL287042A (en) Nlrp3 inflammasome inhibitors
SI4337652T1 (en) Nlrp3 inhibitors
IL306022A (en) Inhibitors of nlrp3 inflammasome
IL280336A (en) Nlrp3 inflammasome inhibitors
CA3262660A1 (en) Nlrp3 inflammasome inhibitors
IL315027A (en) NLRP3 inhibitors
IL319011A (en) Triazinone derivatives as nlrp3 inhibitors
IL314049A (en) Parp7 inhibitors
IL319009A (en) Triazinone derivatives as nlrp3 inhibitors
IL308071A (en) Process for the preparation of nlrp3 inhibitors
EP4251630A4 (en) NLRP3 INFLAMMASOME INHIBITORS SULFONYLUREA
EP4293018A4 (en) Compound serving as nlrp3 inhibitor
PT4337652T (en) Nlrp3 inhibitors
HK40122493A (en) Nlrp3 inflammasome inhibitors
HK40128873A (en) Novel nlrp3 inflammasome inhibitors
HK40099180A (en) Inhibitors of nlrp3 inflammasome
HK40122649A (en) Nlrp3 inhibitors
HK40061653A (en) Nlrp3 inflammasome inhibitors
IL326491A (en) NLRP3 inflammasome inhibitor and its use
CA3286388A1 (en) Nlrp3 inflammasome inhibitors and uses thereof
HK40109676A (en) Inhibitors of nlrp3
HK40117000A (en) N-oxide inhibitors of nlrp3 inflammasome
CA3280638A1 (en) Inhibitors of nlrp3